$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What should I do if resistance to ramucirumab develops? What to pay attention to
2025-10-19 11:44:20
Check Details
Just now! Lung cancer targeted drug Mobotinib is on the market! How much do you know about it?
2025-10-19 11:44:20
Check Details
How much does it cost to buy EGFR-MET bispecific antibody Rybrevant in Hubei? How to use?
2025-10-19 11:44:20
Check Details
How effective is the blockbuster new drug Rybrevant? Are there any serious side effects of Rybrevant?
2025-10-19 11:44:20
Check Details
The response rate of mobotinib, a drug targeting EGFR gene mutation in non-small cell lung cancer, reaches 43%_ Kanghule
2025-10-19 11:44:20
Check Details
Is Mobotinib on the market? Is there a place to sell it in Wuhan?
2025-10-19 11:44:20
Check Details
The anti-tumor drug Pozitinib has a lung cancer disease response rate of up to 90%
2025-10-19 11:44:20
Check Details
What conditions does larotrectinib mainly treat? Is the treatment effective
2025-10-19 11:44:20
Check Details
Will larotrectinib develop resistance? What should you pay attention to when using it
2025-10-19 11:44:20
Check Details
What drug is tepotinib? Is it effective?
2025-10-19 11:44:20
Check Details
【Drug Information】Take you into Tepotinib
2025-10-19 11:44:20
Check Details
LUMYKRAS receives positive opinion from CHMP for the treatment of patients with KRAS G12C mutated advanced NSCLC_ Kanghule
2025-10-19 11:44:20
Check Details
1
2
...
3957
3958
3959
3960
3961
3962
3963
...
4152
4153
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
The Cornerstone Therapy for Adrenocortical Carcinoma and Global Guidelines Update
2
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
3
A Revolutionary Targeted Therapy for Hematological Malignancies
4
A New Option for Advanced Renal Cell Carcinoma Treatment
5
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
6
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
7
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
8
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
9
Adagrasib (Krazati): Full Guide to KRAS G12C Inhibitor for Cancer Treatment
10
Comprehensive Analysis of the Third-Generation EGFR-TKI
11
ATOMIC Study: Atezolizumab Plus Chemo Improves DFS in dMMR Stage III Colon Cancer
12
Oncology Immunotherapy vs Anti-Inflammatory Biologic: Dostarlimab vs Secukinumab - A Mechanism-Centered Comparison